Faculty of Medicine and Health, Musculoskeletal Pain Hub, Charles Perkins Centre, The University of Sydney, Sydney, Australia.
John Walsh Centre for Rehabilitation Research, Sydney Medical School Northern, University of Sydney, Sydney, Australia.
PLoS One. 2023 Feb 28;18(2):e0282205. doi: 10.1371/journal.pone.0282205. eCollection 2023.
There is growing evidence of the anti-inflammatory effect of the anti-diabetic drug metformin and its use to reduce pain. However, we currently lack studies investigating whether metformin is associated with a reduction in chronic back pain prevalence when considering physical activity levels, body mass index (BMI), and age.
To investigate whether use of metformin is associated with lower levels of reporting of chronic back pain in a large cohort with type 2 diabetes when stratified for physical activity, BMI, and age.
This is a cross-sectional study of 21,889 participants with type 2 diabetes who were drawn from the UK Biobank database. We investigated whether people using metformin reported a higher prevalence of chronic low back pain than those who did not. Type 2 diabetes, chronic back pain, and metformin were self-reported. Participants were stratified according to their physical activity level (low, moderate and high), BMI (normal, overweight, and obese), and age (40 to <50; 50 to < 60; and ≥60 years). Logistic regression models were built for each physical activity level, BMI and age category to investigate the prevalence of chronic back pain amongst those using and not using metformin.
Participants who were using metformin and who had low levels of physical activity [OR 0.87, 95%CI 0.78 to 0.96] or who were obese [OR 0.90, 95%CI 0.86 to 0.98] or older [OR 0.85, 95%CI 0.78 to 0.93] had lower odds of reporting chronic back pain than their counterparts.
The anti-diabetic drug metformin might reduce prevalence of chronic low back pain in people who are older, overweight, or less active. These findings should be confirmed in studies using a longitudinal design.
越来越多的证据表明，抗糖尿病药物二甲双胍具有抗炎作用，并可用于减轻疼痛。然而，我们目前缺乏研究来调查当考虑体力活动水平、体重指数（BMI）和年龄时，二甲双胍是否与慢性腰痛患病率的降低有关。
在考虑体力活动、BMI 和年龄分层的情况下，调查 2 型糖尿病大队列中使用二甲双胍是否与慢性腰痛报告率较低相关。
这是一项针对 21889 名 2 型糖尿病患者的横断面研究，这些患者来自英国生物库数据库。我们调查了使用二甲双胍的患者是否比未使用二甲双胍的患者报告慢性下腰痛的患病率更高。2 型糖尿病、慢性腰痛和二甲双胍均为自我报告。根据体力活动水平（低、中、高）、BMI（正常、超重和肥胖）和年龄（40 岁至<50 岁；50 岁至<60 岁；和≥60 岁）对参与者进行分层。在每个体力活动水平、BMI 和年龄类别中建立逻辑回归模型，以调查使用和未使用二甲双胍的患者慢性腰痛的患病率。
与体力活动水平低的参与者相比，使用二甲双胍且体力活动水平低的参与者[OR 0.87，95%CI 0.78 至 0.96]或肥胖的参与者[OR 0.90，95%CI 0.86 至 0.98]或年龄较大的参与者[OR 0.85，95%CI 0.78 至 0.93]报告慢性腰痛的可能性较低。
抗糖尿病药物二甲双胍可能会降低年龄较大、超重或体力活动较少的人慢性下腰痛的患病率。这些发现应在使用纵向设计的研究中得到证实。
